Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - irinotecan hydrochloride trihydrate, quantity: 300 mg - injection, concentrated - excipient ingredients: hydrochloric acid; sodium hydroxide; lactic acid; water for injections; sorbitol - irinotecan hydrochloride is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum. irinotecan hydrochloride is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

Kanada - angleščina - Health Canada

accord healthcare inc - irinotecan hydrochloride (irinotecan hydrochloride trihydrate) - solution - 20mg - irinotecan hydrochloride (irinotecan hydrochloride trihydrate) 20mg - antineoplastic agents

Kanada - angleščina - Health Canada

generic medical partners inc - irinotecan hydrochloride (irinotecan hydrochloride trihydrate) - solution - 20mg - irinotecan hydrochloride (irinotecan hydrochloride trihydrate) 20mg - antineoplastic agents

Malezija - angleščina - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

medispec (m) sdn.bhd - irinotecan hydrochloride trihydrate -

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - irinotecan hydrochloride trihydrate, quantity: 5 mg/ml - injection, concentrated - excipient ingredients: distearoylphosphatidylcholine; cholesterol; sodium methoxy peg-40-carbonyl-distearoylphosphatidylethanolamine; hepes; sodium chloride; water for injections; sucrosofate - onivyde is indicated:,? in combination with oxaliplatin and 5 fluorouracil (5 fu) and leucovorin (lv) for the first-line treatment of metastatic pancreatic adenocarcinoma.,? in combination with 5-fu and lv for the treatment of metastatic pancreatic adenocarcinoma after disease progression following gemcitabine-based therapy.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - irinotecan hydrochloride trihydrate, quantity: 20 mg/ml - injection - excipient ingredients: water for injections; sodium hydroxide; sorbitol; lactic acid - as a component of first line therapy for patients with metastatic carcinoma of the colon or rectum. patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - irinotecan hydrochloride trihydrate, quantity: 20 mg/ml - injection - excipient ingredients: water for injections; sorbitol; lactic acid; sodium hydroxide - as a component of first line therapy for patients with metastatic carcinoma of the colon or rectum. patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - irinotecan hydrochloride trihydrate -

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - irinotecan hydrochloride trihydrate -

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - irinotecan hydrochloride trihydrate, quantity: 40 mg - injection, concentrated - excipient ingredients: sorbitol; hydrochloric acid; water for injections; sodium hydroxide; (s)-lactic acid - tecan is indicated as a component of first line therapy for patients with metastatic carcinoma of the colon or rectum. tecan is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.